AI
NBIX icon

Atria Investments’s Neurocrine Biosciences NBIX Stock Holding History

Atria Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
10,939
+443
+4% +$58.8K 0.02% 865
2025
Q4 		$1.49M Sell
10,496
-354
-3% -$51.3K 0.02% 863
2025
Q3 		$1.52M Buy
10,850
+176
+2% +$23.8K 0.02% 839
2025
Q2 		$1.34M Buy
10,674
+1,415
+15% +$162K 0.02% 903
2025
Q1 		$1.02M Buy
9,259
+4,164
+82% +$528K 0.01% 981
2024
Q4 		$695K Sell
5,095
-400
-7% -$49.5K 0.01% 1157
2024
Q3 		$633K Sell
5,495
-1,307
-19% -$179K 0.01% 1214
2024
Q2 		$936K Buy
+6,802
New +$933K 0.01% 974
2021
Q2 		– Sell
-10,710
Closed -$1.04M – 780
2021
Q1 		$1.04M Buy
+10,710
New +$1.12M 0.02% 690

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atria Investments's NBIX Position: Q1 2026 in Review

Atria Investments increased its Neurocrine Biosciences (NBIX) stake by 4.2% in Q1 2026, buying an estimated $58.8K and bringing the position to 10,939 shares worth $1.44M. The position accounts for 0.02% of the portfolio, ranked #865.

Atria Investments first reported a position in NBIX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.52M in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Atria Investments held 10,939 shares of Neurocrine Biosciences worth $1.44M as of Q1 2026.
  • Atria Investments bought 443 Neurocrine Biosciences shares in Q1 2026, an estimated $58.8K.
  • Neurocrine Biosciences made up 0.02% of Atria Investments's portfolio in Q1 2026, its #865 holding.
  • Atria Investments first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 9 quarters since.
  • Atria Investments's Neurocrine Biosciences position peaked at $1.52M in Q3 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.